Home › Prostate Cancer › Indiana
Prostate Cancer clinical trials in Indiana
24 studies for Prostate Cancer are looking for participants at sites in Indiana.
Cities in Indiana
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- IU Simon Cancer Center, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06465069Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Reid Health, Richmond
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Urology of Indiana - Carmel ( Site 0055), Carmel
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06136650Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- Indiana University, Indianapolis
RecruitingPhase 2/3
Ages 18 to 100 · Men · Updated Sep 22, 2026 · NCT06780670A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Research Site, Greenwood
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 18, 2026 · NCT06952803Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- Indiana University School of Medicine, Indianapolis
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 11, 2026 · NCT06056830Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Goshen Center for Cancer Care, Goshen
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 10, 2026 · NCT05946213A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
- First Urology PSC, Jeffersonville
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 3, 2026 · NCT07723248Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Indiana University, Indianapolis
RecruitingPhase 1
Ages 18 and older · Men · Updated Aug 21, 2026 · NCT04221542A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
- Community Health Network, Indianapolis
RecruitingPhase 1/2
Ages 18 and older · Men · Updated Aug 20, 2026 · NCT06785636Sonablate HIFU International Registry for PC & BPH Patients
- Indiana University Medical Center, Indianapolis
RecruitingObservational study
Ages 18 and older · Men · Updated Aug 13, 2026 · NCT07757490PSMA PET Combined With MRI for the Detection of PCa
- Indiana University, Indianapolis
RecruitingPhase 3Healthy volunteers welcome
Ages 18 and older · Men · Updated Jul 23, 2026 · NCT07052214Study of ORIC-944 in Patients With Metastatic Prostate Cancer
- First Urology, Jeffersonville
RecruitingPhase 1
Ages 18 and older · Men · Updated Jul 9, 2026 · NCT05413421Integrated Cancer Repository for Cancer Research
- Parkview Research Center, Fort Wayne
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
- Parkview Research Center, Fort Wayne
RecruitingPhase 4
Ages 18 to 100 · Men · Updated Jun 4, 2026 · NCT05803941Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
RecruitingPhase 2/3
Ages 18 and older · Men · Updated Apr 8, 2026 · NCT04787744ASCVD Management Using CCTA in Prostate Cancer Patients on ADT
- IU Health Joe and Shelly Schwarz Cancer Center, Carmel
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- Methodist Hospital, Indianapolis
Recruiting
Ages 40 and older · Men · Updated Feb 25, 2026 · NCT05879913A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- First Urology, Jeffersonville
RecruitingPhase 1
Ages 18 and older · Men · Updated Feb 4, 2026 · NCT04729114Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
- Reid Health, Richmond
RecruitingPhase 3
Ages 18 and older · Men · Updated Jan 22, 2026 · NCT06470243cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Floyd, New Albany
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Jan 20, 2026 · NCT05366881Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
RecruitingPhase 2Healthy volunteers welcome
Ages 18 and older · Men · Updated Dec 31, 2025 · NCT06084338Evaluating Tolerability of ePUHRT With Brachytherapy Boost
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
Recruiting
Ages 18 and older · Men · Updated Sep 26, 2025 · NCT06817668Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Reid Health, Richmond
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 11, 2025 · NCT03678025PSMA-PET to Guide Prostatectomy
- Goodman Hall, Indiana Institute for Biomedical Imaging Sciences, Indiana University School of Medicine, Indianapolis
RecruitingPhase 2/3
Ages 40 to 80 · Men · Updated Jan 31, 2025 · NCT05381103From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.